Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

GPs should use obesity drugs longer in diabetes

GPs should trial obesity drugs in patients with diabetes longer than recommended before deciding if they are working, a study concludes.

NICE guidance advises that patients should only be continued on the drugs if they have lost at least 2kg after four weeks, but the researchers found this would deny beneficial treatment to a significant proportion of patients.

The study, which pooled data from seven trials of sibutra-mine, found assessment at four weeks predicted ultimate weight loss with a sensitivity of just 61 per cent and a specificity of 68 per cent. But assessing patients who had lost 4kg at three months increased sensitivity to 79 per cent and specificity to 77 per cent.

Study leader Dr Nick Finer, consultant in obesity medicine at Addenbrooke's Hospital, Cam- bridge, said: 'My advice is that patients with diabetes need to be on sibutramine for longer before you decide they have failed.

'I don't want to tell GPs to breach NICE guidance but the problem with guidelines is they can go out of date.'

Dr Finer, whose study is published in Diabetes, Obesity and Metabolism (March), said the findings were also likely to apply to orlistat.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say